Figures & data
Figure 1 CONSORT flow scheme of the EFECT study.
![Figure 1 CONSORT flow scheme of the EFECT study.](/cms/asset/cacd636f-ae06-4106-9c9b-d048bf7b9f37/dcop_a_115061_f0001_c.jpg)
Figure 2 Study design of the double-blinded placebo-controlled crossover study.
![Figure 2 Study design of the double-blinded placebo-controlled crossover study.](/cms/asset/e6919e16-0c88-4169-88c5-e92d8fc52a22/dcop_a_115061_f0002_b.jpg)
Table 1 Volunteer characteristics (PP population)Table Footnotea
Table 2 Descriptive statistics given as geometric means (SD) (PP population)
Table 3 Changes after application of EIL inhalation solution
Figure 3 Effect of EIL in comparison with the effect of placebo inhalation on inflammatory markers. (A) Effects after the end of the first inhalation period (V1/V2). (B) Effects after the end of the washout phase before starting the second period (V1/V3). Dark gray bars, EIL; light gray bars, placebo. Geometric mean values of individual quotients with 95% confidence intervals are presented. P-values of Student’s t-tests for the EIL–placebo comparison are given if P<0.05.
![Figure 3 Effect of EIL in comparison with the effect of placebo inhalation on inflammatory markers. (A) Effects after the end of the first inhalation period (V1/V2). (B) Effects after the end of the washout phase before starting the second period (V1/V3). Dark gray bars, EIL; light gray bars, placebo. Geometric mean values of individual quotients with 95% confidence intervals are presented. P-values of Student’s t-tests for the EIL–placebo comparison are given if P<0.05.](/cms/asset/cb9e192d-e5da-42b2-a5c6-5ed656445a78/dcop_a_115061_f0003_b.jpg)
Table S1 List of adverse events reported during V1–V4 periods of the EFECT study